Últimas noticias sobre United Therapeutics (NASDAQ:UTHR) Bolsa

United Therapeutics

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

United Therapeutics Corporation - Common Stock

United Therapeutics Corp

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>JP Morgan analyst Eric Joseph initiated coverage on OPKO Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) with a Neutral rating. OPKO Health shares closed at $1.46 on Thursday. <a href="https://www.benzinga.com/quote/OPK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Asiya Merchant initiated coverage on Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) with a Neutral rating and announced a price target of $39. Super Micro Computer shares closed at $35.81 on Thursday. <a href="https://www.benzinga.com/quote/SMCI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Rich Kwas initiated coverage on Sensata Technologies Holding plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ST#NYSE">ST</a>) with an Equal-Weight rating and announced a price target of $20. Sensata Technologies shares closed at $21.64 on Thursday. <a href="https://www.benzinga.com/quote/ST/analyst-ratings">See how other analysts view this stock</a>.</li>
<li> Needham analyst Ryan Koontz initiated coverage on Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) with a Buy rating and announced a price target of $28. Rocket Lab USA shares closed at $21.88 on Thursday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying OPK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="614" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25083217/image-176-1024x614.png" alt="" class="wp-image-888690" style="width:579px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25083217/image-176-1024x614.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25083217/image-176-300x180.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25083217/image-176-768x461.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25083217/image-176.png 1072w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45001899/alphabet-intel-and-3-stocks-to-watch-heading-into-friday">Alphabet, Intel And 3 Stocks To Watch Heading Into Friday</a> </li>
</ul>
Photo via Shutterstock

News

Initiation

Markets

Analyst Ratings

Trading Ideas

RKLB

SMCI

UTHR

This Rocket Lab Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Canaccord Genuity analyst Joseph Vafi downgraded the rating for ASGN Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASGN#NYSE">ASGN</a>) from Buy to Hold and lowered the price target from $115 to $55. ASGN shares closed at $51.76 on Thursday. <a href="https://www.benzinga.com/quote/ASGN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Alexei Gogolev downgraded SS&amp;C Technologies Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSNC#NASDAQ">SSNC</a>) from Overweight to Neutral and lowered the price target from $90 to $86. SS&amp;C Technologies shares closed at $77.43 on Thursday. <a href="https://www.benzinga.com/quote/SSNC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Macquarie analyst Linda Huang downgraded the rating for TAL Education Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAL#NYSE">TAL</a>) from Outperform to Neutral and cut the price target from $14.5 to $10.9. TAL Education shares closed at $8.93 on Thursday. <a href="https://www.benzinga.com/quote/TAL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Tiago Fauth downgraded United Therapeutics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) from Overweight to Equal-Weight and slashed the price target from $395 to $314. United Therapeutics shares closed at $296.42 on Thursday. <a href="https://www.benzinga.com/quote/UTHR/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying UTHR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="632" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25072624/image-173-1024x632.png" alt="" class="wp-image-888521" style="width:611px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25072624/image-173-1024x632.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25072624/image-173-300x185.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25072624/image-173-768x474.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25072624/image-173.png 1065w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45001899/alphabet-intel-and-3-stocks-to-watch-heading-into-friday">Alphabet, Intel And 3 Stocks To Watch Heading Into Friday</a> </li>
</ul>
Photo via Shutterstock

Downgrades

Pre-Market Outlook

ASGN

SSNC

This United Therapeutics Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday

Across the recent three months, 4 analysts have shared their insights on United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $352.0, a high estimate of $425.00, and a low estimate of $314.00. This current average represents a 5.57% decrease from the previous average price target of $372.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1745582487_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive United Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Tiago Fauth &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $314.00&#x7C;$395.00 &#x7C; 
&#x7C;Jessica Fye &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $355.00&#x7C;$357.00 &#x7C; 
&#x7C;Greg Harrison &#x7C;B of A Securities &#x7C;Maintains &#x7C;Neutral &#x7C; $314.00&#x7C;$314.00 &#x7C; 
&#x7C;Andrew Fein &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $425.00&#x7C;$425.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to United Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of United Therapeutics compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of United Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into United Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/UTHR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on United Therapeutics analyst ratings.</a>
<h2>Delving into United Therapeutics's Background</h2>
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
<h3>United Therapeutics: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining United Therapeutics's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 19.72% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: United Therapeutics's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 40.94%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): United Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of 4.8%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): United Therapeutics's ROA excels beyond industry benchmarks, reaching 4.16%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.05.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying United Therapeutics: Insights From 4 Analyst Reviews

Wells Fargo analyst Tiago Fauth downgrades United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) from Overweight to Equal-Weight and lowers the price target from $395 to $314.

Price Target

Wells Fargo Downgrades United Therapeutics to Equal-Weight, Lowers Price Target to $314

JP Morgan analyst Jessica Fye maintains United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) with a Overweight and lowers the price target from $357 to $355.

JP Morgan Maintains Overweight on United Therapeutics, Lowers Price Target to $355

B of A Securities analyst Greg Harrison upgrades United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) from Underperform to Neutral and maintains the price target from $314 to $314.

Upgrades

B of A Securities Upgrades United Therapeutics to Neutral, Maintains Price Target to $314

United Therapeutics Announces Series Of Presentations And Sponsored Events At ATS 2025, Highlighting Pulmonary Hypertension And Fibrosis Studies

United Therapeutics Corporation Says It Will Feature Clinical Data Across Its Commercial And Development Portfolio At International Society For Heart And Lung Transplantation 45th Annual Meeting And Scientific Sessions

HC Wainwright &amp; Co. analyst Andrew Fein reiterates United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) with a Buy and maintains $425 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on United Therapeutics, Maintains $425 Price Target

WIIM

United Therapeutics shares are trading lower after the company reported worse-than-expected Q4 financial results.

United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) reported quarterly earnings of $6.19 per share which missed the analyst consensus estimate of $6.27 by 1.28 percent. This is a 41.97 percent increase over earnings of $4.36 per share from the same period last year. The company reported quarterly sales of $735.90 million which beat the analyst consensus estimate of $734.74 million by 0.16 percent. This is a 19.72 percent increase over sales of $614.70 million the same period last year.

Earnings

United Therapeutics Q4 2024 GAAP EPS $6.19 Misses $6.27 Estimate, Sales $735.90M Beat $734.74M Estimate

AAOI

ABEV

ACAD

ACMR

ADTN

ALEC

AMBA

AMBC

AMSF

ARDT

ARHS

ARIS

ARKO

ASTE

ATEC

AVDX

AVNS

BATRA

BATRK

BBSI

BLMN

BXSL

BYND

CAPL

CDNA

CERT

CLDT

CLPT

COCO

COMM

CORT

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRGY

CSAN

CTRI

DHIL

DMRC

DOLE

DORM

EBAY

ECPG

EHTH

ENIC

ENOV

ERII

ESCA

ESTA

EVTC

FTAI

FWRD

GERN

GOGL

GSX Techedu Inc. American Depositary Shares

GOTU

GRBK

HCAT

HNST

IBTA

IMCR

Earnings Scheduled For February 26, 2025

General

United Therapeutics Commences Enrollment Of The TETON 1 Study to Treat Idiopathic Pulmonary Fibrosis

The study will enroll an initial cohort of six end-stage renal disease (ESRD) patients, expanding to up to 50 participants, and is intended to support a Biologics License Application (BLA) with the FDA.
United Therapeutics expects the first xenotransplant in this trial to be performed around mid-year 2025.

United Therapeutics Says Cleared Its Investigational New Drug Application To Initiate Clinical Study Of Investigational UKidney Derived From 10 Gene-edited Source Pig

Posters include real-world dosing of Tyvaso DPI&#xAE; in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, and data from the BREEZE open-label extension study of Tyvaso DPI detailing its long-term outcomes and dosing in patients with pulmonary arterial hypertension&nbsp;
United Therapeutics is sponsoring the Women in PH Luncheon and the Career Catalyst Luncheon: Speed Mentoring for Early Career PH Professionals
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that five posters across its commercial and development portfolio in pulmonary hypertension (PH) will be presented at the Pulmonary Vascular Research Institute (PVRI) 2025 Annual Congress taking place January 29 through February 1, 2025 in Rio de Janeiro. In addition, professionals from United Therapeutics will participate in two speaking events associated with the congress.
United Therapeutics is also proud to sponsor the Women in PH Luncheon and the Career Catalyst Luncheon: Speed Mentoring for Early Career PH Professionals.

Biotech

United Therapeutics To Present Clinical Data Across Its Commercial And Development Portfolio At The Pulmonary Vascular Research Institute 2025 Annual Congress

UBS analyst Ashwani Verma maintains United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) with a Buy and raises the price target from $415 to $475.

UBS Maintains Buy on United Therapeutics, Raises Price Target to $475

United Therapeutics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NYSE">UTHR</a>) short percent of float has risen 7.82% since its last report. The company recently reported that it has 2.24 million shares sold short, which is 6.62% of all regular shares that are available for trading. Based on its trading volume, it would take traders 9.43 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>United Therapeutics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1735761616_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for United Therapeutics has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing United Therapeutics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, United Therapeutics's peer group average for short interest as a percentage of float is 4.79%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About United Therapeutics?

United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) has outperformed the market over the past 20 years by 6.47% on an annualized basis producing an average annual return of 14.94%. Currently, United Therapeutics has a market capitalization of $16.17 billion. 
Buying $1000 In UTHR: If an investor had bought $1000 of UTHR stock 20 years ago, it would be worth $16,173.45 today based on a price of $362.24 for UTHR at the time of writing.
<h3>United Therapeutics's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733950848_0_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In United Therapeutics 20 Years Ago Would Be Worth This Much Today

United Therapeutics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NYSE">UTHR</a>) short percent of float has risen 4.3% since its last report. The company recently reported that it has 2.30 million shares sold short, which is 6.79% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.06 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>United Therapeutics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732626911_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for United Therapeutics has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing United Therapeutics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, United Therapeutics's peer group average for short interest as a percentage of float is 4.93%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Goldman Sachs analyst Chris Shibutani maintains United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) with a Neutral and raises the price target from $243 to $302.

Goldman Sachs Maintains Neutral on United Therapeutics, Raises Price Target to $302

Press Releases

United Therapeutics Corporation Announces FDA Clearance of its Investigational New Drug Application for the UKidney Xenotransplantation Clinical Trial

United Therapeutics Corporation Announces Full Enrollment of the TETON 1 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis

United Therapeutics Corporation to Report Fourth Quarter and Full Year 2024 Financial Results Before the Market Opens on Wednesday, February 26, 2025

United Therapeutics Corporation to Present at the TD Cowen 45th Annual Health Care Conference

United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results

United Therapeutics Corporation to Present at the Leerink Partners Global Healthcare Conference 2025

United Therapeutics Named to '100 Best Companies to Work For' in 2025 by Fortune Media and Great Place to Work

United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the International Society for Heart and Lung Transplantation 45th Annual Meeting and Scientific Sessions

United Therapeutics Corporation to Report First Quarter 2025 Financial Results Before Market Open on Wednesday, April 30, 2025

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2025 International Conference

Comments

United Therapeutics

Noticias

Últimas noticias sobre United Therapeutics (NASDAQ:UTHR) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL